- Open Access
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
© Park et al; licensee BioMed Central Ltd. 2010
- Received: 18 August 2009
- Accepted: 23 August 2010
- Published: 23 August 2010
Inhibitors of epidermal growth factor receptor (EGFR) have shown dramatic results in a subset of patients with non-small cell lung cancer (NSCLC), and have also been shown to enhance the effect of ionizing radiation (IR). We investigated how gefitinib, an orally given EGFR inhibitor for NSCLC patients, can radiosensitize NSCLC cells.
Experimental Design and Results
In clonogenic survival assays performed in three NSCLC cell lines, gefitinib radiosensitized NCI-H460 and VMRC-LCD but not A549 cells. Gefitinib pretreatment induced multinucleated cells after IR exposure in NCI-H460 and VMRC-LCD, but not in A549 cells. Gefitinib also inhibited activation of ataxia telangiectasia mutated (ATM) after IR-exposure in NCI-H460 and VMRC-LCD, but not in A549 cells. An ATM specific inhibitor increased IR-induced multinucleated cells in both NCI-H460 and A549 cells. Gefitinib pretreatment inhibited the gradual decrease of γH2AX foci relative to time after IR exposure in NCI-H460 but not in A549 cells. Suppression of COX-2 in A549 cells induced multinucleated cells and caused radiosensitization after gefitinib+IR treatment. In contrast, COX-2 overexpression in NCI-H460 cells attenuated the induction of multinucleation and radiosensitization after the same treatment.
Our results suggest that gefitinib radiosensitizes NSCLC cells by inhibiting ATM activity and therefore inducing mitotic cell death, and that COX-2 overexpression in NSCLC cells inhibits this action of gefitinib.
- Epidermal Growth Factor Receptor
- A549 Cell
- Ionize Radiation
Lung cancer is the leading cause of cancer-related deaths in men and women worldwide , and about 80% of lung cancers are non-small cell lung carcinoma (NSCLC). The 5-year survival rate of patients with NSCLC remains among the lowest of all major human cancers at less than 15% . Obviously, novel therapeutic strategies to improve survival of patients with NSCLC are needed. Epidermal growth factor receptor (EGFR) has been regarded as an attractive target molecule for the treatment of various cancers including NSCLC. Recently developed inhibitors of this molecule have shown dramatic results in a subset of patients with NSCLC and have become a routinely applied anticancer agent for this subset of patients [3–5].
EGFR belongs to the ErbB family of plasma membrane receptor tyrosine kinases and controls many important cellular functions. Increased EGFR expression has been observed in many experimental cancer cell lines and human tumors, including NSCLC, and it has been associated with advanced tumor stage, metastasis, and poor prognosis. Previous studies have suggested that high expression of EGFR is associated with resistance to cancer therapy, including radiation therapy [6, 7]. Conversely, EGFR inhibitors have been shown to enhance the effects of ionizing radiation (IR) [8–12], although the effective subset of tumors for radiosensitization by these agents has not yet been defined.
Radiation therapy remains an important part of the treatment regimen for NSCLC, especially for patients with unresectable tumors. The concurrent administration of radiation therapy and chemotherapy is the first-choice treatment option for stage III unresectable NSCLC which makes up over 30% of total NSCLC patients. However, concurrent chemo-radiation therapy is frequently toxic and a significant number of patients suffer from complications such as radiation esophagitis and radiation pneumonitis during or after this treatment [13, 14]. Therefore, it may be beneficial in terms of reducing toxicity and enhancing the effect of radiation therapy if we can administer radiation therapy and EGFR inhibitors concurrently to EGFR-inhibitor-responsive patients instead of administering concurrent chemotherapy. However, the precise underlying mechanisms for the radiosensitizing effect of EGFR inhibitors remained unclear and needed to be addressed to give the basic rationale for the radiation/EGFR inhibitor combined treatment and to further enhance their effects.
In this study, we investigated how gefitinib (ZD1839, Iressa®), an orally given, small-molecular EGFR tyrosine kinase inhibitor that is currently used in the clinic for NSCLC patients , can radiosensitize NSCLC cells in order to understand its mechanism of interaction with IR.
Gefitinib pretreatment enhances the radiosensitivity of NCI-H460 and VMRC-LCD, but not A549 cells
We previously proposed that inhibition of Chk2 phosphorylation may be an underlying mechanism for radiosensitization by gefitinib . Since Chk2 is one of the core molecules in the G2 checkpoint which mediates IR-induced G2 arrest, we examined the effect of gefitinib on IR-induced G2 arrest. Cells were exposed to 15 μmol/L gefitinib for 48 h, irradiated with 6 Gy of γ-radiation, and then further incubated for the indicated time points. IR-induced G2-M arrest was decreased by gefitinib pretreatment compared to IR alone in NCI-H460 and VMRC-LCD cells at 6 or 12 h after IR exposure. However, the G2-M peak was not further decreased but was sustained for more than 24 h while the G2-M peak in IR-alone groups continued to decrease in both cell lines. In contrast, gefitinib did not affect the IR-induced G2-M arrest in A549 cells (Figure 1B). These results led us to hypothesize that gefitinib pretreatment attenuates IR-induced G2 arrest, cells subsequently enter into mitosis due to attenuation of G2 arrest, and the cells that entered into mitosis may be trapped in this cell cycle phase as a form of mitotic catastrophe (MC). This phenomenon was seen in NCI-H460 and VMRC-LCD but not in A549 cells.
Gefitinib pretreatment induces multinucleated cells after IR exposure
Cancer cells severely damaged by IR are known to undergo MC or mitotic cell death (MCD) which is characterized by the formation of micronuclei and/or multinuclei [16, 17]. At the same time, in mammalian cells and particularly in cancer cells, MC is mainly associated with deficiencies in cell cycle checkpoints [18, 19]. The G2-M checkpoint is responsible for blocking mitosis in the case of damaged DNA, and inhibition or knockout of proteins that prevent premature mitosis can induce MC . Therefore, we hypothesized that Chk2 inhibition and attenuation of IR-induced G2 arrest by gefitinib may increase IR-induced MC.
IR-induced ATM and chk2 phosphorylation are inhibited by gefitinib pretreatment
To test whether another EGFR inhibitor would also block IR-induced ATM/Chk2 phosphorylation, we performed the same experiments using cetuximab, which is a monoclonal antibody raised against EGFR. Cetuximab inhibited EGFR activity almost completely at the tested concentration (2 mmol/L, data not shown). In the three cell lines tested, ATM and Chk2 were phosphorylated immediately after exposure to IR. However, in contrast to gefitinib, IR-induced ATM and Chk2 phosphorylation were not inhibited when cells were pretreated with cetuximab before IR exposure (Additional file 1). This finding suggests that inhibition of IR-induced ATM-Chk2 phosphorylation is not a general characteristic of all EGFR inhibitors but a function specific to gefitinib. Therefore, this function of gefitinib may be independent of its inherent EGFR-inhibiting activity.
Gefitinib pretreatment inhibits repair of IR-induced DNA damage
Inhibition of IR-induced ATM phosphorylation causes multinucleated cell formation in NSCLC cells
Collectively, gefitinib may radiosensitize NCI-H460 cells by inhibiting ATM phosphorylation and repair of damaged DNA after IR exposure, and thereby increasing multinucleated cell formation. In contrast, gefitinib may not be able to radiosensitize A549 cells because it does not inhibit IR-induced ATM phosphorylation in these cells and therefore cannot induce multinucleated cell formation and MC.
COX-2 expression of lung cancer cells inhibits radiosensitization by gefitinib
To further test the effect of COX-2 expression on multinucleated cell formation, the number of multinucleated cells was counted in COX-2-overexpressing or -suppressed cells after gefitinib plus IR treatment. In H460-COX2 cells, the number of gefitinib+IR-induced multinucleated cells was decreased significantly compared to H460-Mock cells (Figure 6D). On the contrary, an increased number of multinucleated cells was detected in AS cells compared to AN cells after the same treatment (Figure 6D). These results suggest that COX-2 overexpression in NSCLC cells inhibits gefitinib-induced radiosensitization. Therefore, the lack of radiosensitization of A549 cells by gefitinib seems to be due to COX-2 overexpression.
In the current study, we showed that gefitinib, an orally given EGFR inhibitor that is used currently to treat patients with NSCLC, can radiosensitize NSCLC cells by inhibiting ATM activity which would otherwise promote repair of damaged DNA and prevents MC after IR exposure. Gefitinib inhibited IR-induced ATM phosphorylation in the two NSCLC cell lines (NCI-H460 and VMRC-LCD) that were radiosensitized by this agent, but IR-induced ATM phosphorylation was intact after gefitinib pretreatment in an NSCLC cell line (A549) that was not radiosensitized by this drug. Gefitinib also inhibited repair of DNA double strand breaks and increased multinucleated cell formation after IR exposure in the two former cell lines while it did not in the A549 cell line. We additionally showed that an ATM-specific inhibitor, Ku55933, induced multinucleated cell formation after IR exposure in both NCI-H460 and A549 cells. These findings strongly suggest that ATM inhibition may be a primary underlying mechanism for gefitinib-mediated radiosensitization of NSCLC cells via increased MC. Therefore, gefitinib seems to act as a G2 checkpoint inhibitor.
The concentration of gefitinib used in the current study (15 μmol/L) is considerably higher compared to the plasma concentrations (100-500 nmole/L) that can be achieved after oral administration of gefitinib to patients. However, several pharmacokinetic studies showed extensive uptake of gefitinib into tumor in animal experiments and human investigations. Gefitinib concentrations were 42 fold higher (average tumor concentration was 16.7 μmol/L) in breast tumor and 60 fold higher (average 33.1 μmol/L) in non-small cell lung tumor than in coincident plasma samples taken from human cancer patients [28, 29]. Therefore, the concentration of gefitinib we used for our experiments can be achieved in tumor of cancer patients.
After finding this novel function of gefitinib, we were curious whether this function is shared by other EGFR inhibitors, and whether it is EGFR activity-dependent. We used cetuximab, another EGFR inhibitor that is a monoclonal antibody against the ligand-binding domain of EGFR, to test whether this agent shows the same effect as gefitinib. However, cetuximab did not affect the phosphorylation level of ATM after IR exposure even though it significantly reduced EGFR activity as well as gefitinib did. Therefore, the ATM-inhibiting function of gefitinib seems to be specific to this drug. Cetuximab is also known to radiosensitize mainly head and neck cancer cells [30, 31], however, the mechanism of radiosensitization may be different from that of gefitinib. We also investigated whether EGFR activation using epidermal growth factor (EGF) affects ATM phosphorylation to test for a possible connection between EGFR and ATM signaling pathways. However, we did not find elevated ATM phosphorylation after EGF administration in the tested cancer cells (data not shown). Lack of ATM-inhibiting activity by cetuximab also indicates that gefitinib's ATM-inhibiting function is independent of EGFR activity. Taken together, the ATM-inhibiting activity of gefitinib seems to be specific to this drug and it also seems to be independent of its inherent EGFR-inhibiting activity. This may be a characteristic of small molecular inhibitors that frequently targets more than one protein.
EGFR and KRAS mutations are important factors to predict response to EGFR-tyrosine kinase inhibitors [32–35]. We analyzed the status of EGFR mutations in NCI-H460, A549, and VMRC-LCD and these cells were all EGFR-wild types in exon 18,19,20, and 21 (unpublished data). In addition, according to the published data, NCI-H460 and A549 have KRAS mutations, while VMRC-LCD is a KRAS wild type [36–38]. Since gefitinib radiosensitized NCI-H460 and VMRC-LCD cells but not A549, gefitinib's radiosensitization does not seem to be related to EGFR or KRAS mutational status. A drug sensitivity and a radiosensitization by the drug seem to be mediated by quite different mechanisms.
We were curious as to why A549 cells could not be radiosensitized by gefitinib. This may be an important issue because defining the subset of tumors that respond to this drug is a necessary task to make this drug practical for radiosensitization. We found that COX-2 overexpression in A549 cells inhibited the gefitinib's MC-inducing activity. Suppression of COX-2 in A549 cells allowed for the induction of MC and radiosensitization after gefitinib plus IR treatment, while COX-2 overexpression in NCI-H460 cells reduced MC-induction and the degree of radiosensitization achieved with same treatment (Figure 6). These results show that COX-2 overexpression in NSCLC can play a critical role, although it may not be the only factor, in the development of resistance to gefitinib's radiosensitizing activity.
How COX-2 can induce this resistance to gefitinib is currently unclear. Recently, we reported that COX-2 overexpressing cancer cells upregulate ataxia telangiectasia and rad3-related (ATR) expression and activity, and that upregulated ATR induces resistance to DNA damaging agents such as IR or hydroxyurea . Therefore, upregulated ATR activity in COX-2 overexpressing cancer cells may compensate for the ATM activity inhibited by gefitinib, and thereby prevent MC. On the other hand, COX-2 may directly recover gefitinib-inhibited ATM phosphorylation using as yet undefined mechanisms. Further investigation is warranted to understand the precise mechanisms involved in the resistance to gefitinib induced by COX-2.
In conclusion, we propose that gefitinib radiosensitizes NSCLC cells through inhibiting IR-induced ATM activation, and therefore acts as a G2 checkpoint inhibitor to induce mitotic catastrophic cell death. COX-2-overexpressing cells show resistance to gefitinib's radiosensitizing activity. Our findings may contribute to the application of gefitinib or other EGFR inhibitors for combined treatment with radiation therapy in patients with NSCLC.
Gefitinib was provided by AstraZeneca UK Ltd. (London, United Kingdom), Cetuximab was provided by Merck (Darmstadt, Germany), Ku55933, an ATM kinase specific inhibitor, was acquired from Calbiochem (Darmstadt, Germany).
Human lung large cell carcinoma cell line NCI-H460 and human lung adenocarcinoma cell line A549 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human lung adenocarcinoma cell line VMRC-LCD was obtained from the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). Cyclooxygenase(COX)-2 knocked down A549 cells by RNA interference  and COX-2 overexpressing NCI-H460 stable cells have been established as described previously . All cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 2 mmol/L glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin (Life Technologies, Gaithersburg, MD, USA) at 37°C in an atmosphere of 5% CO2 and 95% air. All cell lines were qualified for mycoplasma contamination using MycoAlert® Mycoplasma detection kit (Lonza, Rockland, ME, USA).
The effectiveness of the combined treatment with gefitinib and IR was assessed by clonogenic survival assays as described previously . The surviving fraction (SF) of cells exposed to gefitinib plus IR was normalized by dividing by the SF of gefitinib alone.
To analyze cell cycle, 1.5 ~ 3 × 105 cells were plated into 60 mm dishes for the determination of each data point. After 24 h, the cells were exposed to the appropriate concentrations of gefitinib or vehicle (DMSO) for 48 h, and then exposed to 6 Gy of γ-rays using the Gammacell 3000 Elan system (MDS Nordion Inc., Ontario, Canada). Cells were further incubated in media which contained either the drug or the vehicle for the indicated times. The cells were trypsinized (retaining all floating cells), fixed with 70% ethanol at 4°C overnight, washed with phosphate buffered saline (PBS), then incubated with 50 μg/ml of propidium iodide (PI; Sigma, St. Louis, MO, USA) and 5 μg/ml of RNase A (Amresco, Solon, OH, USA) at room temperature for 0.5 h. The number of cells at each cell cycle was evaluated with the FACS Calibur system (Becton Dickinson, San Jose, CA, USA).
Immunofluorescence and confocal microscopy
Cells were grown on coverslips, treated with 15 μmol/L gefitinib or vehicle (DMSO) for 48 h and then exposed to 6 Gy of γ-rays. After incubation in CO2 incubator, cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min and permeabilized in 0.5% Triton X-100 for 15 min. Anti-phosphor-ataxia telangiectasia mutated (ATM) monoclonal antibody (Rockland, Gilbertsville, PA, USA), anti-phosphor-checkpoint kinase 2 (Chk2) polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA) or γ-H2AX monoclonal antibody (Millipore, Billerica, MA, USA) were diluted (1:500), and incubated with cells for overnight at 4°C. Samples were then incubated for 1 h at room temperature with Alexa 488 anti-mouse and Alexa 594 anti-rabbit secondary antibodies (Molecular Probes, Eugene, OR, USA). Nuclear staining was done with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) (Wako, Osaka, Japan). Cells were washed and mounted using mounting solution (Dako, Denmark). The images were taken with confocal microscopy (Carl Zeiss, Germany).
Harvested cells were used for immunoblotting as described previously . Equal amounts of protein were analyzed in triplicate by SDS-polyacrylamide gel electrophoresis. The following antibodies were used; anti-phosphor-Ser1981-ATM (Rockland), anti-phosphor-Thr68-Chk2 (Cell Signaling), anti-ATM (Novus, Littleton, CO, USA), anti-Chk2 (Cell Signaling) and anti-β-Actin (Sigma) antibodies. Immunoreactive proteins were detected with secondary antibodies and visualized using an enhanced chemiluminescence detection system (Amersham Bioscience, Piscataway, NJ, USA).
In vitro kinase assay for ATM
Cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.4, 1.0% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 20 mM sodium fluoride, 0.2 mM sodium orthovanadate, 1.0 mM EDTA, 0.2 mM PMSF). The cell lysates were centrifuged at 15,000 g for 20 min at 4°C to remove cell debris. Equal amounts of protein were incubated with anti-ATM (Novus) antibody for overnight. After addition of Protein A-agarose (Santa Cruz Biotechnology), the lysates were incubated for an additional 4 h. The beads were washed twice with the lysis beffer, once with the kinase beffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT), and then incubated with kinase buffer that contains 1 mM ATP, 1 ug Chk1 kinase protein (Cell signaling) as a substrate for 20 min at 37°C. After incubation, the beads were boiled for 5 min with 5× concentrated electrophoresis sample buffer to terminate the reaction. The supernatants were separated by SDS-PAGE, and immunoblotted with ATM (Novus), Chk1, pSer345 Chk1 (Cell signaling) antibodies. Immunoreactive proteins were detected with secondary antibodies and visualized using an enhanced chemiluminescence detection system (Amersham Bioscience, Piscataway, NJ, USA).
Statistical significance was examined using Student's t-tests. The two-sample t test was used for two-group comparisons. Values were reported as means ± standard errors (SE). P values < 0.05 were considered significant.
This work was supported by the National Cancer Center Grant (0710380-3).
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006View ArticlePubMedGoogle Scholar
- Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001, 7: 2958-2970.PubMedGoogle Scholar
- Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK: Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol. 2006, 1: 367-376. 10.1097/01243894-200605000-00018View ArticlePubMedGoogle Scholar
- Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K: Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009, 9: 17-35. 10.1586/14737126.96.36.199View ArticlePubMedGoogle Scholar
- Jiang H: Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol. 2009, 39: 137-150. 10.1093/jjco/hyn139View ArticlePubMedGoogle Scholar
- Ochs JS: Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys. 2004, 58: 941-949. 10.1016/j.ijrobp.2003.09.094View ArticlePubMedGoogle Scholar
- Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995, 19: 183-232. 10.1016/1040-8428(94)00144-IView ArticlePubMedGoogle Scholar
- Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE: Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 2008, 14: 1266-1273. 10.1158/1078-0432.CCR-07-1606PubMed CentralView ArticlePubMedGoogle Scholar
- She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res. 2003, 9: 3773-3778.PubMedGoogle Scholar
- Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002, 8: 3250-3258.PubMedGoogle Scholar
- Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H: Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res. 2006, 12: 4989-4999. 10.1158/1078-0432.CCR-05-2259View ArticlePubMedGoogle Scholar
- Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G: EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer. 2008, 123: 209-216. 10.1002/ijc.23488View ArticlePubMedGoogle Scholar
- Chapet O, Kong FM, Lee JS, Hayman JA, Ten Haken RK: Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 2005, 77: 176-181. 10.1016/j.radonc.2005.10.001View ArticlePubMedGoogle Scholar
- Wynn RB, Mehta V: Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial. Semin Oncol. 2005, 32: S99-104. 10.1053/j.seminoncol.2005.03.017View ArticlePubMedGoogle Scholar
- Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62: 5749-5754.PubMedGoogle Scholar
- Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G: Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003, 63: 8241-8247.PubMedGoogle Scholar
- Miranda EI, Santana C, Rojas E, Hernandez S, Ostrosky-Wegman P, Garcia-Carranca A: Induced mitotic death of HeLa cells by abnormal expression of c-H-ras. Mutat Res. 1996, 349: 173-182.View ArticlePubMedGoogle Scholar
- Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004, 23: 2825-2837. 10.1038/sj.onc.1207528View ArticlePubMedGoogle Scholar
- Roninson IB, Broude EV, Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001, 4: 303-313. 10.1054/drup.2001.0213View ArticlePubMedGoogle Scholar
- de Bruin EC, Medema JP: Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev. 2008, 34: 737-749. 10.1016/j.ctrv.2008.07.001View ArticlePubMedGoogle Scholar
- Lobrich M, Jeggo PA: The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007, 7: 861-869. 10.1038/nrc2248View ArticlePubMedGoogle Scholar
- Iliakis G, Wang Y, Guan J, Wang H: DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene. 2003, 22: 5834-5847. 10.1038/sj.onc.1206682View ArticlePubMedGoogle Scholar
- Harper JW, Elledge SJ: The DNA damage response: ten years after. Mol Cell. 2007, 28: 739-745. 10.1016/j.molcel.2007.11.015View ArticlePubMedGoogle Scholar
- Kuo LJ, Yang LX: Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008, 22: 305-309.PubMedGoogle Scholar
- Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS, Xu L: Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys. 2009, 74: 1217-1225. 10.1016/j.ijrobp.2009.03.057PubMed CentralView ArticlePubMedGoogle Scholar
- Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K: Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008, 14: 6496-6504. 10.1158/1078-0432.CCR-08-0468View ArticlePubMedGoogle Scholar
- Kim YM, Park SY, Pyo H: Cyclooxygenase-2 (COX-2) negatively regulates expression of EGFR and causes resistance to gefitinib in COX-2 overexpressing cancer cells. Mol Cancer Res. 2009, 7: 1367-1377. 10.1158/1541-7786.MCR-09-0004View ArticlePubMedGoogle Scholar
- Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A: Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anticancer Drugs. 2009, 20: 856-866. 10.1097/CAD.0b013e32833034e1View ArticlePubMedGoogle Scholar
- McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F: Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2005, 4: 641-649. 10.1158/1535-7163.MCT-04-0329View ArticlePubMedGoogle Scholar
- Astsaturov I, Cohen RB, Harari PM: EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2006, 6: 691-710. 10.2174/156800906779010191View ArticlePubMedGoogle Scholar
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422View ArticlePubMedGoogle Scholar
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938View ArticlePubMedGoogle Scholar
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500. 10.1126/science.1099314View ArticlePubMedGoogle Scholar
- Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005, 23: 5900-5909. 10.1200/JCO.2005.02.857View ArticlePubMedGoogle Scholar
- Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008, 26: 1472-1478. 10.1200/JCO.2007.13.0062View ArticlePubMedGoogle Scholar
- Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer. 2006, 118: 209-214. 10.1002/ijc.21290View ArticlePubMedGoogle Scholar
- Romanowska M, Maciag A, Smith AL, Fields JR, Fornwald LW, Kikawa KD, Kasprzak KS, Anderson LM: DNA damage, superoxide, and mutant K-ras in human lung adenocarcinoma cells. Free Radic Biol Med. 2007, 43: 1145-1155. 10.1016/j.freeradbiomed.2007.07.004View ArticlePubMedGoogle Scholar
- Kashii T, Mizushima Y, Nakagawa K, Monno S, Yano S: Amplification of the N-myc oncogene in an adenocarcinoma cell line of the lung. Anticancer Res. 1992, 12: 621-624.PubMedGoogle Scholar
- Kim YM, Lee EJ, Park SY, Cho KH, Kim JY, Pyo H: Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol Cancer Res. 2009, 7: 1158-1168. 10.1158/1541-7786.MCR-08-0493View ArticlePubMedGoogle Scholar
- Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res. 2005, 65: 9501-9509. 10.1158/0008-5472.CAN-05-0220View ArticlePubMedGoogle Scholar
- Kang HK, Lee E, Pyo H, Lim SJ: Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther. 2005, 4: 1358-1363. 10.1158/1535-7163.MCT-05-0139View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.